Screener
Zymeworks ZYME ZW171 — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Research and development collaborations | $4,590 | $48,726 | $6,998 | $75,836 |
| Operating expenses: | ||||
| Research and development | 27,435 | 34,449 | 61,892 | 70,187 |
| General and administrative | 19,335 | 14,951 | 34,404 | 31,936 |
| Total operating expenses | 46,770 | 49,400 | 96,296 | 102,123 |
| Loss from operations | (42,180) | (674) | (89,298) | (26,287) |
| Other (expense) income: |
Item 1. Financial Statements
FAQ
- What is Zymeworks's ZW171 — R&D?
- Zymeworks (ZYME) reported ZW171 — R&D of -$458K in Q2 2026.
- What does ZW171 — R&D mean?
- This metric represents the total investment and resource allocation dedicated to the research and development activities for the specific therapeutic candidate or platform identified as ZW171. It captures the strategic commitment to advancing this asset through the clinical pipeline, reflecting the company's focus on innovation and product development. Investors use this to gauge the intensity of development efforts and the prioritization of this specific asset within the broader R&D portfolio.
Ask your AI about Zymeworks's zw171 — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude